Bristol Myers Squibb announced positive topline results from TRANSFORM, a global, randomized, multicenter Phase III study evaluating Breyanzi (lisocabtagene maraleucel) as a second-line treatment in adults with relapsed… read more.
Interview and article by Christine Clark. The anti-tumour effects of ivermectin have been described in the literature and the liposomal delivery system developed by Mountain Valley MD could… read more.
It’s long been known that people living with HIV experience a loss of white matter in their brains. As opposed to “gray matter,” which is composed of the… read more.
The FDA is alerting health care providers to no longer implant end-stage heart failure patients with Medtronic’s Heartware Ventricular Assist Device (HVAD) System due to a growing body… read more.
Interview and article by Christine Clark. Liposomal drug delivery holds out the prospect of oral drug administration without the need for water and more economical use of oral… read more.
Immunotherapy with pembrolizumab after surgery significantly improves disease-free survival among patients with the most prevalent form of kidney cancer, clear-cell renal carcinoma. Researchers reported this finding on June… read more.
Genentech, a member of the Roche Group announced the latest data from three pivotal Phase III studies of Venclexta (venetoclax) – CLL14, MURANO and VIALE-A – to be… read more.
Article written by Bruce Sylvester. When treated with adjuvant olaparib after completion of local treatment and neoadjuvant or adjuvant chemotherapy, patients with high-risk, HER2-negative early breast cancer and… read more.
Interview and article by Christine Clark. Patented solubilisation technology improves the bioavailability of oral ivermectin and makes possible the formulation of an ivermectin injection for human use, according… read more.
Medtronic plc announced it has received FDA approval for Vanta, a high performance recharge-free implantable neurostimulator (INS) with a device life that can be optimized up to 11… read more.
Researchers at UVA Cancer Center have unveiled important new insights into how hormones known as androgens act on our cells — and the discovery could boost efforts to… read more.
Biogen and Eisai, Co., Ltd. announced that the FDA has granted accelerated approval for Aduhelm (aducanumab-avwa) as the first and only Alzheimer’sdisease treatment to address a defining pathology… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
